Why is this ASX All Ords stock jumping 7% today?

This stock is ending the week strongly. Let's find out what is getting investors excited.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Orthocell Ltd (ASX: OCC) shares are catching the eye again on Friday.

In morning trade, the ASX All Ords stock is up 7% to $1.51.

A woman jumps for joy with a rocket drawn on the wall behind her.

Image source: Getty Images

Why is this ASX All Ords stock jumping today?

Investors have been buying the regenerative medicine company's shares following the release of an announcement relating to its flagship Remplir product.

Remplir is a collagen wrap used in nerve repair surgery to assist surgeons to improve outcomes in the repair and regeneration of damaged nerves.

It was recently given the thumbs up by the US Food & Drug Administration, paving the way for the company to start generating revenue in the country.

Orthocell is targeting a large global addressable nerve repair market estimated to be worth in excess of US$3.5 billion.

What is today's news?

According to the release, the company has added a further eight distributors for Remplir, taking the total number of US distributors signed to 12.

Management notes that the signing of distributors has progressed well ahead of expectations with the company previously only targeting 10 distributors in place by 30 June. It feels that the rapid signing of these new distributors is a testament to the quality of Remplir and the distributors' belief in being able to generate strong sales for the product in the US.

Following these new appointments, the ASX All Ords stock's distributor group collectively covers 21 US states. And with these relationships non-exclusive, the company intends to continue signing additional distributors to expand access to the US market.

'Confident'

Commenting on the news, Orthocell's CEO and managing director, Paul Anderson, said:

It's very pleasing to see such rapid progress on the expansion of our US distributor network so soon after receiving US FDA clearance in April. We're well ahead of the targets we had set ourselves and expect that to translate to first US Remplir sales this quarter.

Our US team has been working tirelessly leading up to the product launch and we're confident we have the right strategy to drive market penetration of the US. For us, that means a combination of experienced internal employees complemented by a portfolio of distributors who have active sales channels to reach and engage our customers. We expect to grow our portfolio of distributors too.

Following today's strong gain, this ASX All Ords stock is now up almost 300% since this time last year.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Orthocell. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A woman scratches her head, thinking is this a no-brainer?
Healthcare Shares

Does this ASX 200 stock's fall make it a no-brainer buy?

Despite a major transformation, this stock is down more than 20%. Is this an opportunity?

Read more »

Scientist looking at a laptop thinking about the share price performance.
Healthcare Shares

ASX 200 healthcare shares down 33% in a year as heavyweights hit multi-year lows

Eight of the 10 largest healthcare shares are trading at or close to multi-year or 52-week lows.

Read more »

Stock market chart in green with a rising arrow symbolising a rising share price.
Healthcare Shares

Up 2,075% in a year, why is the 4DMedical share price rocketing again on Friday?

Investors just sent 4DMedical shares surging another 20% on Friday. But why?

Read more »

Businessman working and using Digital Tablet new business project finance investment at coffee cafe.
Healthcare Shares

Buy, hold, sell: What is Ord Minnett saying about this popular ASX 200 stock?

Here's what the broker is saying about this stock.

Read more »

A man in a shirt and tie looks to the horizon holding his hand above his eyes as if to shield the sun so he can see better.
Healthcare Shares

Why is everyone talking about 4DX shares this week?

It's all eyes on the healthcare stock this week.

Read more »

A bearded man holds both arms up diagonally and points with his index fingers to the sky with a thrilled look on his face.
Healthcare Shares

$10,000 invested in this ASX healthcare share a year ago is now worth $36,500

This stock has experienced a dramatic price increase.

Read more »

A male doctor and a woman in scrubs in the foreground smile.
Healthcare Shares

The ASX healthcare stocks with the biggest upside according to brokers

These two healthcare stocks could be value buys.

Read more »

Cropped shot of a young female scientist working on her computer in the laboratory.
Healthcare Shares

Here's one reason why experts think the CSL share price can rise 65%!

There’s more than one reason why experts are excited by the potential of CSL.

Read more »